BRCA 1/BRCA 2 PATHOGENIC/LIKELY PATHOGENIC VARIANT PATIENTS WITH BREAST, OVARIAN, AND OTHER CANCERS
Osman K.1,*, Ahmet K.2, Hilmi T.3, İlker N.O.4, Ercan Ö.5, Devrim Ç.5, Murat S.1, Emre Ç.6, İlhan H.6, Mustafa G.7, Yüksel Ü.7, Bahiddin Y.8, Cihan E.9, Mehmet Ali N. Ş.9, Emrah E.10, Umut D.10, Zeynep O.11, Mehmet Ali K.12, Ali G.2, İvo G.2, Erkan Ö.2, Muhammet B. H.2, Bülent E.2, Selma D.12, Sernaz U.2, Mahmut G.4, Hakan G.12, İrfan Ç.2
*Corresponding Author: Assoc. Prof. Osman Köstek, MD, Marmara University, School of Medicine, Department of Medical Oncology Address: Marmara University, Basıbuyuk Campus, Maltepe, Istanbul, Turkey. Email: osmankostek@hotmail.com, Telephone: +90 554 585 73 90
page: 5

MATERIAL AND METHODS

Study subjects. This retrospective multicenter study includes the results of sequencing analysis of 200 patients (190 women, 10 men) who have been directed to genetic counseling with an indication BRCA1/ BRCA2 test from different regions of Turkey. This study was approved by the local ethics committee. DNA isolation. Genomic DNA was isolated from peripheral blood samples by using the EasyOne DNA isolation system (Qiagen, Hilden, Germany) and isolated DNA samples were assessed spectrophotometrically with NanoDrop (Thermo Fisher Scientific). Samples whose A260/280 values were between 1.8-2.0 were used for Next-Generation Sequencing. Low quality DNA samples were re-extracted from stored blood samples. Next Generation Sequencing (NGS). For NGS, a QIAseq Targeted Amplicon Panel (Qiagen, Hilden, Germany), covering the coding regions of BRCA1 and BRCA2 genes with 20bp intron padding primers was used. Amplicon libraries were prepared according to the instructions of the manufacturer (Qiagen, Hilden, Germany). Pooled libraries were sequenced on the MiSeq System (Illumina, San Diego, CA, USA) following the target enrichment process. Fastq generation was performed on MiseqReporter Software (Illumina, San Diego, CA). Quality control of sequenced amplicons and variant call format (vcf) file generation were performed using QCI analysis (Qiagen, Hilden, Germany) software. Variant analysis was performed using Ingenuity and Clinical Insight Softwares (Qiagen, Hilden, Germany), and all rare and novel variants were visually controlled by using IGV 2.4.8 (www.broadinstitute.com). Segregation analysis of family members were performed using Sanger Sequencing with in-house designed primer sets covering the mutation regions. Data Analysis and Variant Classification. The latest versions of gnomAD [4], dbSNP [5], and ClinVar [6] databases were considered for comparing known variant frequencies. HGMD [7] and literature accessions were also considered. ACMG 2015 [8] guidelines were used for final classification of the variants . All statistical analyses were performed using IBM SPSS ver. 22 (SPSS Inc., Chicago, IL). Data were presented as median (25th-75th interquartile range). Categorical variables were reported as frequencies and group percentages. Progression-free survival was defined as the time from the date of initial diagnosis to disease progression or death due to any cause. The Pearson chi-square test was used to compare the categorical variables of the two groups, and the independent sample t-test or Mann–Whitney U-test was used to compare the continuous variables of the two groups. The Kaplan–Meier method was used for the survival analysis. P < 0.05 was considered statistically significant.



Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006